Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1981 Mar;34(3):292–302. doi: 10.1136/jcp.34.3.292

Human platelet monoamine oxidase activity in health and disease: a review.

M Sandler, M A Reveley, V Glover
PMCID: PMC1146480  PMID: 6453137

Abstract

The most readily available source of monoamine oxidase in man is the platelet, although only the B form of the enzyme is represented in this site. Platelet activity is higher in women than in men. The enzyme activity is generally stable and is partly under genetic control. There is some evidence that individuals with low activity have a higher psychiatric morbidity than those with high activity. Despite some negative studies, the consensus of publication dealing with schizophrenia, migraine, and alcoholism find that mean platelet monoamine oxidase activity in the patient group is lower than in the controls. Values are raised in unipolar depression. Technical differences, or patient or control group heterogeneity, might well account for the absence of unanimity in the literature. A considerable degree of overlap between patient and control values, whatever the clinical diagnosis, appears to be the standard finding. Apart from these neuropsychiatric disturbances, platelet monoamine oxidase activity is raised in megaloblastic anaemia and reduced in iron deficiency anaemia. Although altered enzyme activity values may be linked to abnormal platelet populations in some of the haematological disorders discussed, in general the causes of abnormal platelet monoamine oxidase activity are unknown.

Full text

PDF
302

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anselmi B., Buffoni F., Curradi C., Del Bianco P. L., Sicuteri F. Monoamine oxidase defect in essential arterial hypertension. A single dose pargyline test. Monogr Neural Sci. 1976;3:115–123. doi: 10.1159/000399343. [DOI] [PubMed] [Google Scholar]
  2. Ask A. L., Bök J. A., Heyden T., Ross S. B., Unge C., Wetterberg L., Eiduson S., Kobayashi K. Platelet monoamine oxidase in a pedigree with schizophrenia: an interlaboratory project. Clin Genet. 1979 Apr;15(4):289–299. doi: 10.1111/j.1399-0004.1979.tb01737.x. [DOI] [PubMed] [Google Scholar]
  3. BERGERET B., BLASCHKO H., HAWES R. Occurrence of an amine oxidase in horse serum. Nature. 1957 Nov 23;180(4595):1127–1128. doi: 10.1038/1801127b0. [DOI] [PubMed] [Google Scholar]
  4. Belmaker R. H., Ebbesen K., Ebstein R., Rimon R. Platelet monoamine oxidase in schizophrenia and manic-depressive illness. Br J Psychiatry. 1976 Sep;129:227–232. doi: 10.1192/bjp.129.3.227. [DOI] [PubMed] [Google Scholar]
  5. Belmaker R. H., Ebstein R., Rimon R., Wyatt R. J., Murphy D. L. Electrophoresis of platelet monoamine oxidase in schizophrenia and manic-depressive illness. Acta Psychiatr Scand. 1976 Jul;54(1):67–72. doi: 10.1111/j.1600-0447.1976.tb00094.x. [DOI] [PubMed] [Google Scholar]
  6. Belmaker R. H., Murphy D. L., Wyatt R. J., Loriaux D. L. Human platelet monoamine oxidase changes during the menstrual cycle. Arch Gen Psychiatry. 1974 Oct;31(4):553–556. doi: 10.1001/archpsyc.1974.01760160093019. [DOI] [PubMed] [Google Scholar]
  7. Belmaker R. H., Reches A., Ebstein R. P. Platelet monoamine oxidase in schizophrenia. Lancet. 1977 Oct 15;2(8042):821–821. doi: 10.1016/s0140-6736(77)90755-3. [DOI] [PubMed] [Google Scholar]
  8. Berger P. A., Ginsburg R. A., Barchas J. D., Murphy D. L., Wyatt R. J. Platelet monoamine oxidase in chronic schizophrenic patients. Am J Psychiatry. 1978 Jan;135(1):95–99. doi: 10.1176/ajp.135.1.95. [DOI] [PubMed] [Google Scholar]
  9. Berrettini W. H., Prozialeck W., Vogel W. H. Decreased platelet monoamine oxidase activity in chronic schizophrenia, shown with novel substrates. Arch Gen Psychiatry. 1978 May;35(5):600–605. doi: 10.1001/archpsyc.1978.01770290082007. [DOI] [PubMed] [Google Scholar]
  10. Berrettini W. H., Vogel W. H., Clouse R. Platelet monoamine oxidase in chronic schizophrenia. Am J Psychiatry. 1977 Jul;134(7):805–807. doi: 10.1176/ajp.134.7.805. [DOI] [PubMed] [Google Scholar]
  11. Berrettini W. H., Vogel W. H. Evidence for an endogenous inhibitor of platelet MAO in chronic schizophrenia. Am J Psychiatry. 1978 May;135(5):605–607. doi: 10.1176/ajp.135.5.605. [DOI] [PubMed] [Google Scholar]
  12. Berrettini W. H., Vogel W. H., Ladman R. K. Effects of lithium therapy on mao in manic-depressive illness. Am J Psychiatry. 1979 Jun;136(6):836–838. doi: 10.1176/ajp.136.6.836. [DOI] [PubMed] [Google Scholar]
  13. Blackwell B., Marley E., Price J., Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry. 1967 Apr;113(497):349–365. doi: 10.1192/bjp.113.497.349. [DOI] [PubMed] [Google Scholar]
  14. Bockar J., Roth R., Heninger G. Increased human platelet monoamine oxidase activity during lithium carbonate therapy. Life Sci. 1974 Dec 15;15(12):2109–2118. doi: 10.1016/0024-3205(74)90027-7. [DOI] [PubMed] [Google Scholar]
  15. Bond P. A., Cundall R. L., Falloon I. R. Monoamine oxidase (MAO) of platelets, plasma, lymphocytes and granulocytes in schizophrenia. Br J Psychiatry. 1979 Apr;134:360–365. doi: 10.1192/bjp.134.4.360. [DOI] [PubMed] [Google Scholar]
  16. Bond P. A., Cundall R. L. Properties of monoamine oxidase (MAO) in human blood platelets, plasma, lymphocytes and granulocytes. Clin Chim Acta. 1977 Oct 15;80(2):317–326. doi: 10.1016/0009-8981(77)90039-0. [DOI] [PubMed] [Google Scholar]
  17. Brown J. B. Platelet MAO and alcoholism. Am J Psychiatry. 1977 Feb;134(2):206–207. doi: 10.1176/ajp.134.2.206. [DOI] [PubMed] [Google Scholar]
  18. Buchsbaum M. S., Coursey R. D., Murphy D. L. The biochemical high-risk paradigm: behavioral and familial correlates of low platelet monoamine oxidase activity. Science. 1976 Oct 15;194(4262):339–341. doi: 10.1126/science.968488. [DOI] [PubMed] [Google Scholar]
  19. Buchsbaum M. S., Haier R. J., Murphy D. L. Suicide attempts, platelet monoamine oxidase and the average evoked response. Acta Psychiatr Scand. 1977 Jul;56(1):69–79. doi: 10.1111/j.1600-0447.1977.tb06665.x. [DOI] [PubMed] [Google Scholar]
  20. Buchsbaum M. S., Murphy D. L., Coursey R. D., Lake C. R., Zeigler M. G. Platelet monoamine oxidase, plasma dopamine-beta-hydroxylase and attention in a "biochemical high risk" sample. J Psychiatr Res. 1978;14(1-4):215–224. doi: 10.1016/0022-3956(78)90024-9. [DOI] [PubMed] [Google Scholar]
  21. Bussone G., Giovannini P., Boiardi A., Boeri R. A study of the activity of platelet monoamine oxidase in patients with migraine headaches or with 'cluster headaches'. Eur Neurol. 1977;15(3):157–162. doi: 10.1159/000114806. [DOI] [PubMed] [Google Scholar]
  22. Bök J. A., Wetterberg L., Modrzewska K. Schizophrenia in a North Swedish geographical isolate, 1900--1977. Epidemiology, genetics and biochemistry. Clin Genet. 1978 Dec;14(6):373–394. doi: 10.1111/j.1399-0004.1978.tb02105.x. [DOI] [PubMed] [Google Scholar]
  23. Carpenter W. T., Jr, Murphy D. L., Wyatt R. J. Platelet monoamine oxidase activity in acute schizophrenia. Am J Psychiatry. 1975 Apr;132(4):438–441. doi: 10.1176/ajp.132.4.438. [DOI] [PubMed] [Google Scholar]
  24. Challacombe D. N., Sandler M., Southgate J. Decreased duodenal monoamine oxidase activity in coeliac disease. Arch Dis Child. 1971 Apr;46(246):213–215. doi: 10.1136/adc.46.246.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Cohen D. J., Young J. G., Roth J. A. Platelet monoamine oxidase in early childhood autism. Arch Gen Psychiatry. 1977 May;34(5):534–537. doi: 10.1001/archpsyc.1977.01770170044003. [DOI] [PubMed] [Google Scholar]
  26. Collins G. G., Pryse-Davies J., Sandler M., Southgate J. Effect of pretreatment with oestradiol, progesterone and DOPA on monoamine oxidase activity in the rat. Nature. 1970 May 16;226(5246):642–643. doi: 10.1038/226642a0. [DOI] [PubMed] [Google Scholar]
  27. Cookson I. B., Owen F., Ridges A. P. Platelet monoamine oxidase activity during the course of a schizophreniform psychosis. Psychol Med. 1975 Aug;5(3):314–316. doi: 10.1017/s0033291700056701. [DOI] [PubMed] [Google Scholar]
  28. Corash L., Tan H., Gralnick H. R. Heterogeneity of human whole blood platelet subpopulations. I. Relationship between buoyant density, cell volume, and ultrastructure. Blood. 1977 Jan;49(1):71–87. [PubMed] [Google Scholar]
  29. Couch J. R., Hassanein R. S. Platelet aggregability in migraine. Neurology. 1977 Sep;27(9):843–848. doi: 10.1212/wnl.27.9.843. [DOI] [PubMed] [Google Scholar]
  30. Crow T. J., Baker H. F., Cross A. J., Joseph M. H., Lofthouse R., Longden A., Owen F., Riley G. J., Glover V., Killpack W. S. Monoamine mechanisms in chronic schizophrenia: post-mortem neurochemical findings. Br J Psychiatry. 1979 Mar;134:249–256. doi: 10.1192/bjp.134.3.249. [DOI] [PubMed] [Google Scholar]
  31. Davidson J., Mcleod M. N., Linnoila M., Kurland A. A., White H. L. Platelet MAO inhibition following tricyclic antidepressant therapy. Am J Psychiatry. 1978 May;135(5):603–605. doi: 10.1176/ajp.135.5.603. [DOI] [PubMed] [Google Scholar]
  32. Day H. J., Holmsen H., Zucker M. B. Methods for separating platelets from blood and plasma. Thromb Diath Haemorrh. 1975 Jun 30;33(3):648–654. [PubMed] [Google Scholar]
  33. DeLisi L. E., Neckers L. M., Staub R. A., Zalcman S. J., Wyatt R. J. Lymphocyte monoamine oxidase activity and chronic schizophrenia. Psychiatry Res. 1980 May;2(2):179–186. doi: 10.1016/0165-1781(80)90075-x. [DOI] [PubMed] [Google Scholar]
  34. Demisch L., von der Mühlen H., Bochnik H. J., Seiler N. Substrate-typic changes of platelet monoamine oxidase activity in sub-types of schizophrenia. Arch Psychiatr Nervenkr (1970) 1977 Dec 28;224(4):319–329. doi: 10.1007/BF00341614. [DOI] [PubMed] [Google Scholar]
  35. Deshmukh S. V., Meyer J. S. Cyclic changes in platelet dynamics and the pathogenesis and prophylaxis of migraine. Headache. 1977 Jul;17(3):101–108. doi: 10.1111/j.1526-4610.1977.hed1703101.x. [DOI] [PubMed] [Google Scholar]
  36. Domino E. F., Khanna S. S. Decreased blood platelet MAO activity in unmedicated chronic schizophrenic patients. Am J Psychiatry. 1976 Mar;133(3):323–326. doi: 10.1176/ajp.133.3.323. [DOI] [PubMed] [Google Scholar]
  37. Donnelly C. H., Murphy D. L. Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase. Biochem Pharmacol. 1977 May 1;26(9):853–858. doi: 10.1016/0006-2952(77)90398-7. [DOI] [PubMed] [Google Scholar]
  38. Donnelly E. F., Murphy D. L., Waldman I. N., Buchsbaum M. S., Coursey R. D. Psychological characteristics corresponding to low versus high platelet monoamine oxidase activity. Biol Psychiatry. 1979 Apr;14(2):375–383. [PubMed] [Google Scholar]
  39. Edwards D. J., Spiker D. G., Kupfer D. J., Foster G., Neil J. F., Abrams L. Platelet monoamine oxidase in affective disorders. Arch Gen Psychiatry. 1978 Dec;35(12):1443–1446. doi: 10.1001/archpsyc.1978.01770360047005. [DOI] [PubMed] [Google Scholar]
  40. Elsworth J. D., Glover V., Sandler M. Tele-Methylhistamine is a specific MAO B substrate in man. Psychopharmacology (Berl) 1980;69(3):287–290. doi: 10.1007/BF00433097. [DOI] [PubMed] [Google Scholar]
  41. Feldman J. M., Roche J. Effect of hyper- and hypothyroidism on platelet monoamine oxidase activity and serotonin metabolism. Metabolism. 1977 Jun;26(6):657–664. doi: 10.1016/0026-0495(77)90087-7. [DOI] [PubMed] [Google Scholar]
  42. Feldman J. M., Roche J. Effect of oral contraceptives on platelet monoamine oxidase, monoamine excretion, and adrenocortical function. Clin Pharmacol Ther. 1976 Dec;20(6):670–675. doi: 10.1002/cpt1976206670. [DOI] [PubMed] [Google Scholar]
  43. Fowler C. J., Oreland L., Marcusson J., Winblad B. Titration of human brain monoamine oxidase -A and -B by clorgyline and L-deprenil. Naunyn Schmiedebergs Arch Pharmacol. 1980 Apr;311(3):263–272. doi: 10.1007/BF00569406. [DOI] [PubMed] [Google Scholar]
  44. Friedhoff A. J., Miller J. C., Karpatkin S. Heterogeneity of human platelets. VII. Platelet monoamine oxidase activity in normals and patients with autoimmune thrombocytopenic purpura and reactive thrombocytosis: its relationship to platelet protein density. Blood. 1978 Feb;51(2):317–323. [PubMed] [Google Scholar]
  45. Friedhoff A. J., Miller J. C., Weisenfreund J. Human platelet MAO in drug-free and medicated schizophrenic patients. Am J Psychiatry. 1978 Aug;135(8):952–955. doi: 10.1176/ajp.135.8.952. [DOI] [PubMed] [Google Scholar]
  46. Friedman E., Shopsin B., Sathananthan G., Gershon S. Blood platelet monoamine oxidase activity in psychiatric patients. Am J Psychiatry. 1974 Dec;131(12):1392–1394. [PubMed] [Google Scholar]
  47. Gentil V., Greenwood M. H., Lader M. H. The effect of adrenaline on human platelet MAO activity. Psychopharmacologia. 1975 Oct 31;44(2):187–190. doi: 10.1007/BF00421008. [DOI] [PubMed] [Google Scholar]
  48. Giller E. L., Jr, Bierer L., Rubinow D., Docherty J. P. Platelet MAO Vmax and Km in chronic schizophrenic subjects. Am J Psychiatry. 1980 Jan;137(1):97–98. doi: 10.1176/ajp.137.1.97. [DOI] [PubMed] [Google Scholar]
  49. Giller E., Jr, Jatlow P., Bialos D., Harkness L., Docherty J. P. Platelet MAO and amitriptyline treatment. Psychiatry Res. 1980 Jul;2(3):259–265. doi: 10.1016/0165-1781(80)90018-9. [DOI] [PubMed] [Google Scholar]
  50. Glover V., Elsworth J. D., Sandler M. Dopamine oxidation and its inhibition by (-)-deprenyl in man. J Neural Transm Suppl. 1980;(16):163–172. doi: 10.1007/978-3-7091-8582-7_18. [DOI] [PubMed] [Google Scholar]
  51. Glover V., Reveley M. A., Sandler M. A monoamine oxidase inhibitor in human urine. Biochem Pharmacol. 1980 Feb;29(3):467–470. doi: 10.1016/0006-2952(80)90534-1. [DOI] [PubMed] [Google Scholar]
  52. Glover V., Sandler M., Grant E., Rose F. C., Orton D., Wilkinson M., Stevens D. Transitory decrease in platelet monoamine-oxidase activity during migraine attacks. Lancet. 1977 Feb 19;1(8008):391–393. doi: 10.1016/s0140-6736(77)92604-6. [DOI] [PubMed] [Google Scholar]
  53. Groshong R., Baldessarini R. J., Gibson D. A., Lipinski J. F., Axelrod D., Pope A. Activities of types A and B MAO and catechol-o-methyltransferase in blood cells and skin fibroblasts of normal and chronic schizophrenic subjects. Arch Gen Psychiatry. 1978 Oct;35(10):1198–1205. doi: 10.1001/archpsyc.1978.01770340048004. [DOI] [PubMed] [Google Scholar]
  54. Hanington E. Migraine: A blood disorder? Lancet. 1978 Sep 2;2(8088):501–503. doi: 10.1016/s0140-6736(78)92222-5. [DOI] [PubMed] [Google Scholar]
  55. Hussein L., Sindarto E., Goedde H. W. Twin studies and substrate differences in platelet monoamine oxidase activity. Hum Hered. 1980;30(2):65–70. doi: 10.1159/000153104. [DOI] [PubMed] [Google Scholar]
  56. Johnston J. P. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol. 1968 Jul;17(7):1285–1297. doi: 10.1016/0006-2952(68)90066-x. [DOI] [PubMed] [Google Scholar]
  57. Joseph M. H., Owen F., Baker H. F., Bourne R. C. Platelet serotonin concentration and monoamine oxidase activity in unmedicated chronic schizophrenic and in schizoaffective patients. Psychol Med. 1977 Feb;7(1):159–162. doi: 10.1017/s0033291700023230. [DOI] [PubMed] [Google Scholar]
  58. Knoll J., Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol. 1972;5:393–408. [PubMed] [Google Scholar]
  59. Kruk Z. L., Moffett A., Scott D. F. Platelet monoamine oxidase activity in epilepsy. J Neurol Neurosurg Psychiatry. 1980 Jan;43(1):68–70. doi: 10.1136/jnnp.43.1.68. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. LEVINE R. J., OATES J. A., VENDSALU A., SJOERDSMA A. Studies on the metabolism of aromatic amines in relation to altered thyroid function in man. J Clin Endocrinol Metab. 1962 Dec;22:1242–1250. doi: 10.1210/jcem-22-12-1242. [DOI] [PubMed] [Google Scholar]
  61. LEVINE R. J., SJOERDSMA A. Monoamine oxidase activity in human tissues and intestinal biopsy specimens. Proc Soc Exp Biol Med. 1962 Jan;109:225–227. doi: 10.3181/00379727-109-27160. [DOI] [PubMed] [Google Scholar]
  62. Landowski J., Lysiak W., Angielski S. Monoamine oxidase activity in blood platelets from patients with cyclophrenic depressive syndromes. Biochem Med. 1975 Dec;14(4):347–354. doi: 10.1016/0006-2944(75)90053-8. [DOI] [PubMed] [Google Scholar]
  63. Leckman J. F., Gershon E. S., Nichols A. S., Murphy D. L. Reduced MAO activity in first-degree relatives of individuals with bipolar affective disorders. A preliminary report. Arch Gen Psychiatry. 1977 May;34(5):601–606. doi: 10.1001/archpsyc.1977.01770170111011. [DOI] [PubMed] [Google Scholar]
  64. Lewinsohn R., Böhm K., Glover V., Sandler M. A benzylamine oxidase distinct from monoamine oxidase B--widespread distribution in man and rat. Biochem Pharmacol. 1978;27(14):1857–1863. doi: 10.1016/0006-2952(78)90033-3. [DOI] [PubMed] [Google Scholar]
  65. Lewinsohn R., Glover V., Sandler M. Development of benzylamine oxidase and monoamine oxidase A and B in man. Biochem Pharmacol. 1980 May 1;29(9):1221–1230. doi: 10.1016/0006-2952(80)90278-6. [DOI] [PubMed] [Google Scholar]
  66. Major L. F., Murphy D. L. Platelet and plasma amine oxidase activity in alcoholic individuals. Br J Psychiatry. 1978 Jun;132:548–554. doi: 10.1192/bjp.132.6.548. [DOI] [PubMed] [Google Scholar]
  67. Mallinson C. N., Bloom S. R., Warin A. P., Salmon P. R., Cox B. A glucagonoma syndrome. Lancet. 1974 Jul 6;2(7871):1–5. doi: 10.1016/s0140-6736(74)91343-9. [DOI] [PubMed] [Google Scholar]
  68. Mann J. Altered platelet monoamine oxidase activity in affective disorders. Psychol Med. 1979 Nov;9(4):729–736. doi: 10.1017/s0033291700034048. [DOI] [PubMed] [Google Scholar]
  69. Mann J., Chiu E. Platelet monoamine oxidase activity in Huntington's chorea. J Neurol Neurosurg Psychiatry. 1978 Sep;41(9):809–812. doi: 10.1136/jnnp.41.9.809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Mann J., Thomas K. M. Platelet monoamine oxidase activity in schizophrenia. Relationship to disease, treatment, institutionalization and outcome. Br J Psychiatry. 1979 Apr;134:366–371. [PubMed] [Google Scholar]
  71. Mazumder R. C., Glover V., Sandler M. Progesterone provokes a selective rise of monoamine oxidase A in the female genital tract. Biochem Pharmacol. 1980 Jun 15;29(12):1857–1859. doi: 10.1016/0006-2952(80)90152-5. [DOI] [PubMed] [Google Scholar]
  72. Meltzer H. Y., Arora R. C., Babar R., Jackman H., Nasr S., Pscheidt G., Smith M., Strahilevitz M. Platelet monoamine oxidase activity and schizophrenia. Arch Gen Psychiatry. 1980 Mar;37(3):357–357. doi: 10.1001/archpsyc.1980.01780160127015. [DOI] [PubMed] [Google Scholar]
  73. Meltzer H. Y., Arora R. C. Skeletal muscle MAO activity in the major psychoses. Relationship with platelet and plasma MAO activities. Arch Gen Psychiatry. 1980 Mar;37(3):333–339. doi: 10.1001/archpsyc.1980.01780160103012. [DOI] [PubMed] [Google Scholar]
  74. Meltzer H. Y., Stahl S. M. Platelet monoamine oxidase activity and substrate preferences in schizophrenic patients. Res Commun Chem Pathol Pharmacol. 1974 Feb;7(2):419–431. [PubMed] [Google Scholar]
  75. Mendelson W. B., Buchsbaum M. S., Murphy D. L., Wyatt R. J., Gillin J. C. Platelet monoamine oxidase activity and human sleep. Commun Psychopharmacol. 1978;2(6):539–544. [PubMed] [Google Scholar]
  76. Metselaar D. Possible selection of virulent poliovirus strains in Third-World countries. Lancet. 1976 Jan 24;1(7952):174–176. doi: 10.1016/s0140-6736(76)91276-9. [DOI] [PubMed] [Google Scholar]
  77. Murphy D. L., Belmaker R., Carpenter W. T., Wyatt R. J. Monoamine oxidase in chronic schizophrenia: Studies of hormonal and other factors affecting enzyme activity. Br J Psychiatry. 1977 Feb;130:151–158. doi: 10.1192/bjp.130.2.151. [DOI] [PubMed] [Google Scholar]
  78. Murphy D. L., Belmaker R., Wyatt R. J. Monamine oxidase in schizophrenia and other behavioral disorders. J Psychiatr Res. 1974;11:221–247. doi: 10.1016/0022-3956(74)90097-1. [DOI] [PubMed] [Google Scholar]
  79. Murphy D. L., Costa J. L., Shafer B., Corash L. Monoamine oxidase activity in different density gradient fractions of human platelets. Psychopharmacology (Berl) 1978 Oct 31;59(2):193–197. doi: 10.1007/BF00427757. [DOI] [PubMed] [Google Scholar]
  80. Murphy D. L., Donnelly C. H., Miller L., Wyatt R. J. Platelet monamine oxidase in chronic schizophrenia. Some enzyme characteristics relevant to reduced activity. Arch Gen Psychiatry. 1976 Nov;33(11):1377–1381. doi: 10.1001/archpsyc.1976.01770110105011. [DOI] [PubMed] [Google Scholar]
  81. Murphy D. L., Donnelly C. H., Miller L., Wyatt R. J. Platelet monamine oxidase in chronic schizophrenia. Some enzyme characteristics relevant to reduced activity. Arch Gen Psychiatry. 1976 Nov;33(11):1377–1381. doi: 10.1001/archpsyc.1976.01770110105011. [DOI] [PubMed] [Google Scholar]
  82. Murphy D. L., Redmond D. E., Jr, Baulu J., Donnelly C. H. Platelet monoamine oxidase activity in 116 normal rhesus monkeys: relations between enzyme activity and age, sex and genetic factors. Comp Biochem Physiol C. 1978;60(2):105–108. doi: 10.1016/0306-4492(78)90081-3. [DOI] [PubMed] [Google Scholar]
  83. Murphy D. L., Weiss R. Reduced monoamine oxidase activity in blood platelets from bipolar depressed patients. Am J Psychiatry. 1972 May;128(11):1351–1357. doi: 10.1176/ajp.128.11.1351. [DOI] [PubMed] [Google Scholar]
  84. Murphy D. L., Wyatt R. J. Reduced monoamine oxidase activity in blood platelets from schizophrenic patients. Nature. 1972 Jul 28;238(5361):225–226. doi: 10.1038/238225a0. [DOI] [PubMed] [Google Scholar]
  85. Nies A., Robinson D. S., Lamborn K. R., Lampert R. P. Genetic control of platelet and plasma monoamine oxidase activity. Arch Gen Psychiatry. 1973 Jun;28(6):834–838. doi: 10.1001/archpsyc.1973.01750360060008. [DOI] [PubMed] [Google Scholar]
  86. Orsulak P. J., Schildkraut J. J., Schatzberg A. F., Herzog J. M. Differences in platelet monoamine oxidase activity in subgroups of schizophrenic and depressive disorders. Biol Psychiatry. 1978 Dec;13(6):637–647. [PubMed] [Google Scholar]
  87. Owen F., Acker W., Bourne R. C., Frith C. D., Riley G. J. The effect on human monoamine oxidase activity of subcutaneous injections of adrenaline. Biochem Pharmacol. 1977 Nov 1;26(21):2065–2067. doi: 10.1016/0006-2952(77)90018-1. [DOI] [PubMed] [Google Scholar]
  88. Owen F., Cross A. J., Crow T. J., Johnstone E. C., Lofthouse R., Riley G. J. Platelet monamine oxidase in schizophrenia. Lancet. 1977 Nov 19;2(8047):1082–1082. doi: 10.1016/s0140-6736(77)91922-5. [DOI] [PubMed] [Google Scholar]
  89. Pandey G. N., Dorus E., Shaughnessy R., Davis J. M. Genetic control of platelet monoamine oxidase activity: studies on normal families. Life Sci. 1979 Sep 24;25(13):1173–1178. doi: 10.1016/0024-3205(79)90140-1. [DOI] [PubMed] [Google Scholar]
  90. Perris C., d'Elia G. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. X. Mortality, suicide and life-cycles. Acta Psychiatr Scand Suppl. 1966;194:172–189. [PubMed] [Google Scholar]
  91. Potkin S. G., Cannon H. E., Murphy D. L., Wyatt R. J. Are paranoid schizophrenics biologically different from other schizophrenics? N Engl J Med. 1978 Jan 12;298(2):61–66. doi: 10.1056/NEJM197801122980201. [DOI] [PubMed] [Google Scholar]
  92. Redmond D. E., Jr, Baulu J., Murphy D. L., Loriaux D. L., Zeigler M. G., Lake C. R. The effects of testosterone on plasma and platelet monoamine oxidase (MAO) an plasma dopamine-beta-hydroxylase (DBH) activities in the male rhesus monkey. Psychosom Med. 1976 Sep-Oct;38(5):315–326. doi: 10.1097/00006842-197609000-00004. [DOI] [PubMed] [Google Scholar]
  93. Reveley M. A., Glover V., Slander M., Coppen A. Absence of platelet monamine oxidase inhibition during amitriptyline or zimelidine treatment. Br J Clin Pharmacol. 1979 Oct;8(4):375–378. doi: 10.1111/j.1365-2125.1979.tb04725.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Robins E., Guze S. B. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry. 1970 Jan;126(7):983–987. doi: 10.1176/ajp.126.7.983. [DOI] [PubMed] [Google Scholar]
  95. Robinson D. S., Davis J. M., Nies A., Ravaris C. L., Sylwester D. Relation of sex and aging to monoamine oxidase activity of human brain, plasma, and platelets. Arch Gen Psychiatry. 1971 Jun;24(6):536–539. doi: 10.1001/archpsyc.1971.01750120052009. [DOI] [PubMed] [Google Scholar]
  96. Roth J. A., Gillis C. N. Deamination of beta-phenylethylamine by monoamine oxidase--inhibition by imipramine. Biochem Pharmacol. 1974 Sep 15;23(18):2537–2545. doi: 10.1016/0006-2952(74)90176-2. [DOI] [PubMed] [Google Scholar]
  97. Roth J. A., Whittemore R. M., Shakarjian M. P., Eddy B. J. Inhibition of human brain type A and B monoamine oxidase by chloropromazine and metabolites. Commun Psychopharmacol. 1979;3(4):235–243. [PubMed] [Google Scholar]
  98. Sandler M., Youdim M. B., Hanington E. A phenylethylamine oxidising defect in migraine. Nature. 1974 Jul 26;250(464):335–337. doi: 10.1038/250335a0. [DOI] [PubMed] [Google Scholar]
  99. Schildkraut J. J., Herzog J. M., Orsulak P. J., Edelman S. E., Shein H. M., Frazier S. H. Reduced platelet monoamine oxidase activity in a subgroup of schizophrenic patients. Am J Psychiatry. 1976 Apr;133(4):438–440. doi: 10.1176/ajp.133.4.438. [DOI] [PubMed] [Google Scholar]
  100. Schooler C., Zahn T. P., Murphy D. L., Buchsbaum M. S. Psychological correlates of monoamine oxidase activity in normals. J Nerv Ment Dis. 1978 Mar;166(3):177–186. doi: 10.1097/00005053-197803000-00003. [DOI] [PubMed] [Google Scholar]
  101. Schwartz M. A., Wyatt R. J., Yang H. Y., Neff N. H. Multiple forms of brain monoamine oxidase in schizophrenic and normal individuals. Arch Gen Psychiatry. 1974 Oct;31(4):557–560. doi: 10.1001/archpsyc.1974.01760160097020. [DOI] [PubMed] [Google Scholar]
  102. Shaskan E. G., Becker R. E. Letter: Platelet monoamine oxidase in schizophrenics. Nature. 1975 Feb 20;253(5493):659–660. doi: 10.1038/253659b0. [DOI] [PubMed] [Google Scholar]
  103. Sicuteri F., Buffoni F., Anselmi B., Del Bianco P. L. An enzyme (MAO) defect on the platelets in migraine. Res Clin Stud Headache. 1970;3:245–251. [PubMed] [Google Scholar]
  104. Southgate J., Grant E. C., Pollard W., Pryse-Davies J., Sandler M. Cyclical variations in endometrial monoamine oxidase: correlation of histochemical and quantitative biochemical assays. Biochem Pharmacol. 1968 May;17(5):721–726. doi: 10.1016/0006-2952(68)90008-7. [DOI] [PubMed] [Google Scholar]
  105. Sullivan J. L., Cavenar J. O., Jr, Stanfield C. N., Hammett E. B. Reduced MAO activity in platelets and lymphocytes of chronic schizophrenics. Am J Psychiatry. 1978 May;135(5):597–598. doi: 10.1176/ajp.135.5.597. [DOI] [PubMed] [Google Scholar]
  106. Sullivan J. L., Dackis C., Stanfield C. In vivo inhibition of platelet MAO activity by tricyclic antidepressants. Am J Psychiatry. 1977 Feb;134(2):188–190. doi: 10.1176/ajp.134.2.188. [DOI] [PubMed] [Google Scholar]
  107. Sullivan J. L., Stanfield C. N., Schanberg S., Cavenar J. Platelet monoamine oxidase and serum dopamine-beta-hydroxylase activity in chronic alcoholics. Arch Gen Psychiatry. 1978 Oct;35(10):1209–1212. doi: 10.1001/archpsyc.1978.01770340059005. [DOI] [PubMed] [Google Scholar]
  108. Sullivan J., Stanfield C. N., Dackis C. Platelet MAO activity in schizophrenia and other psychiatric illnesses. Am J Psychiatry. 1977 Oct;134(10):1098–1103. doi: 10.1176/ajp.134.10.1098. [DOI] [PubMed] [Google Scholar]
  109. Takahashi S., Kanai H., Miyamoto Y. Monoamine oxidase activity in blood platelets from autistic children. Folia Psychiatr Neurol Jpn. 1977;31(4):597–603. doi: 10.1111/j.1440-1819.1977.tb00130.x. [DOI] [PubMed] [Google Scholar]
  110. Takahashi S., Yamane H., Tani N. Reduction of blood platelet monoamine oxidase activity in schizophrenic patients on phenothiazines. Folia Psychiatr Neurol Jpn. 1975;29(3):207–214. doi: 10.1111/j.1440-1819.1975.tb02337.x. [DOI] [PubMed] [Google Scholar]
  111. Van Kammen D. P., Marder S. R., Murphy D. L., Bunney W. E., Jr MAO activity, csf amine metabolites, and drug-free improvement in schizophrenia. Am J Psychiatry. 1978 May;135(5):567–569. doi: 10.1176/ajp.135.5.567. [DOI] [PubMed] [Google Scholar]
  112. WURTMAN R. J., AXELROD J. A SENSITIVE AND SPECIFIC ASSAY FOR THE ESTIMATION OF MONOAMINE OXIDASE. Biochem Pharmacol. 1963 Dec;12:1439–1441. doi: 10.1016/0006-2952(63)90215-6. [DOI] [PubMed] [Google Scholar]
  113. White H. L., McLeod M. N., Davidson J. R. Platelet monoamine oxidase activity in schizophrenia. Am J Psychiatry. 1976 Oct;133(10):1191–1193. doi: 10.1176/ajp.133.10.1191. [DOI] [PubMed] [Google Scholar]
  114. Wiberg A., Gottfries C. G., Oreland L. Low platelet monoamine oxidase activity in human alcoholics. Med Biol. 1977 Jun;55(3):181–186. [PubMed] [Google Scholar]
  115. Wiberg A. Increase in platelet monoamine oxidase activity during controlled abstinence after alcohol abuse. Med Biol. 1979 Apr;57(2):133–134. [PubMed] [Google Scholar]
  116. Winblad B., Gottfries C. G., Oreland L., Wiberg A. Monoamine oxidase in platelets and brains of non-psychiatric and non-neurological geriatric patients. Med Biol. 1979 Apr;57(2):129–132. [PubMed] [Google Scholar]
  117. Wise C. D., Potkin S., Bridge P., Wyatt R. J. An endogenous inhibitor of platelet MAO activity in chronic schizophrenia: failure to replicate. Am J Psychiatry. 1979 Oct;136(10):1336–1337. doi: 10.1176/ajp.136.10.1336. [DOI] [PubMed] [Google Scholar]
  118. Wyatt R. J., Murphy D. L., Belmaker R., Cohen S., Donnelly C. H., Pollin W. Reduced monoamine oxidase activity in platelets: a possible genetic marker for vulnerability to schizophrenia. Science. 1973 Mar 2;179(4076):916–918. doi: 10.1126/science.179.4076.916. [DOI] [PubMed] [Google Scholar]
  119. Wyatt R. J., Murphy D. L. Low platelet monoamine oxidase activity and schizophrenia. Schizophr Bull. 1976;2(1):77–89. doi: 10.1093/schbul/2.1.77. [DOI] [PubMed] [Google Scholar]
  120. Wyatt R. J., Potkin S. G., Murphy D. L. Platelet monoamine oxidase activity in schizophrenia: a review of the data. Am J Psychiatry. 1979 Apr;136(4A):377–385. [PubMed] [Google Scholar]
  121. Yang H. Y., Neff N. H. Beta-phenylethylamine: a specific substrate for type B monoamine oxidase of brain. J Pharmacol Exp Ther. 1973 Nov;187(2):365–371. [PubMed] [Google Scholar]
  122. Youdim M. B., Grahame-Smith D. G., Woods H. F. Some properties of human platelet monoamine oxidase in iron-deficiency anaemia. Clin Sci Mol Med. 1976 Jun;50(6):479–485. doi: 10.1042/cs0500479. [DOI] [PubMed] [Google Scholar]
  123. Yu P. H., Boulton A. A. Activation of platelet monoamine oxidase by plasma in the human. Life Sci. 1979 Jul 2;25(1):31–36. doi: 10.1016/0024-3205(79)90486-7. [DOI] [PubMed] [Google Scholar]
  124. Zeller E. A., Boshes B., Davis J. M., Thorner M. Letter: Molecular aberration in platelet monoamine oxidase in schizophrenia. Lancet. 1975 Jun 21;1(7921):1385–1385. doi: 10.1016/s0140-6736(75)92301-6. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES